

Transfusion-Related Acute Lung Injury (TRALI) in Postoperative Anesthesia Care Unit (PACU) After One Unit of Platelets: A Case Report

Received 07/14/2022

Review began 08/23/2022

Review ended 09/06/2022

Published 09/17/2022

© Copyright 2022

Perez-Viloria et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Miguel E. Perez-Viloria¹, Kalei Lopez², Fayeza Malik², Puja Yatham², Olga Lopez³, Kei S. Oh⁴, Sarah Alghamdi⁴, Guillermo Garcia¹

1. Anesthesiology, Mount Sinai Medical Center, Miami, USA 2. Anesthesiology, Florida International University, Herbert Wertheim College of Medicine, Miami, USA 3. Medicine, Florida International University, Herbert Wertheim College of Medicine, Miami, USA 4. Pathology, Mount Sinai Medical Center, Miami, USA

Corresponding author: Miguel E. Perez-Viloria, mperezv87@gmail.com

Abstract

Transfusion-related acute lung injury (TRALI) following transfusion of all plasma-containing blood products is a rare but serious syndrome characterized by the acute onset of non-cardiogenic pulmonary edema with severe hypoxemia with or without symptoms of hypotension, pinkish frothy secretions, fever, and cyanosis. In this report, we present a case of a 66-year-old female with a medical history significant for hypertension, hyperlipidemia, hepatitis C, liver cirrhosis, tobacco use disorder, metastatic spindle cell carcinoma of the lung status post chemotherapy who developed TRALI after administration of one unit of platelets. Although a rare occurrence, there can be a considerable risk of TRALI following transfusion of all plasma-containing blood products and there is great importance in considering each patient's risk factors for TRALI development prior to blood product administration.

Categories: Anesthesiology, Pulmonology, Hematology

Keywords: postoperative complications in the pacu, platelet transfusion, anesthesia recovery period, transfusion-related acute lung injury, case reports

Introduction

Transfusion-related acute lung injury (TRALI) following transfusion of plasma-containing blood products is a rare but serious syndrome that is characterized by the acute onset of non-cardiogenic pulmonary edema with severe hypoxemia within 6 h of receiving a transfusion of any blood product [1-2]. Although resolution can occur within 48-96 h of supportive care [3]. TRALI is the leading cause of serious morbidity and mortality associated with transfused blood components reported to the United States Food and Drug Administration (FDA) [4].

General risk factors for developing TRALI vary and include a history of smoking, alcohol use disorder, liver disease, shock prior to a transfusion, systemic inflammation, and pre-existing pulmonary injury [5-7]. Transfusion-specific risk factors for TRALI involve the receipt of multiple units of blood products, and the receipt of plasma from a previously pregnant donor who has developed anti-leukocyte antibodies from alloimmunization [5, 8]. Furthermore, evidence amounts to the significant role that neutrophils play in the development of TRALI considering that patients with leukemia and lymphoma, who often present with significant neutropenia, have been reported to have a lower incidence of TRALI overall [9]. Current understanding of the triggers of TRALI suggests that the presence of cytokines and lipids in the transfused blood product activates the recipient's pulmonary neutrophils that cause direct damage to the lungs, leading to a change in vascular permeability and the onset of pulmonary edema [10].

The three major types of TRALI that differ in their pathophysiological onset include the following: antibody-mediated, non-antibody-mediated, and possible-TRALI types [2]. Antibody-mediated TRALI is thought to develop when leukocyte-directed antibodies contained within the donor plasma of a transfused blood product bind to the cognate antigen in the transfusion-recipient, resulting in a capillary leak and subsequent lung injury [11]. Despite this conceptualization of injury, antibodies are not identified in the transfused product in nearly 20% of TRALI cases regardless of the use of sensitive assays. Non-antibody mediated TRALI is postulated to be due to exposure to some other type of biological reactive molecules contained within the plasma of the transfused blood product which ultimately serves as the inciting factor leading to lung injury [12]. The third major type is possible-TRALI which includes the same criteria as TRALI in addition to the risk factors for ARDS such as sepsis and pneumonia [13]. Interestingly, a prominent pretransfusion elevation in inflammatory cytokines such as IL-8 is expected whereas the presence of anti-leukocyte antibodies is rare thus contributing to the unique pathophysiology behind possible-TRALI [14].

The expected clinical presentation of TRALI involves rapid onset of dyspnea, tachypnea, fever, pink-colored secretions with a frothy consistency, hypotension or hypertension, cyanosis, and transient leukopenia [4, 15]. A diagnosis of TRALI relies on the exclusion of other causes of acute pulmonary edema following

How to cite this article

Perez-Viloria M E, Lopez K, Malik F, et al. (September 17, 2022) Transfusion-Related Acute Lung Injury (TRALI) in Postoperative Anesthesia Care Unit (PACU) After One Unit of Platelets: A Case Report. Cureus 14(9): e29274. DOI 10.7759/cureus.29274

transfusion which includes but is not limited to sepsis from pneumonia, anaphylaxis, cardiogenic pulmonary edema, and transfusion-associated circulatory overload (TACO) [16]. In particular, distinguishing between TRALI and TACO often can be quite difficult given their overlapping symptomatology. Whereas TACO typically presents as pulmonary cardiogenic edema, TRALI can be expected to manifest as non-cardiogenic pulmonary edema and identified using the key diagnostic features found in the table further described in the discussion [17]. In general, diagnostic criteria for TRALI includes (1) acute onset hypoxemia within 6 h of transfusion; (2) a PAO₂/FiO₂ ratio of less than 300 mmHg or oxygen saturation of less than 90% on room air; (3) bilateral pulmonary infiltrates on chest radiograph; and (4) pulmonary artery wedge pressure < 18 mmHg with no evidence of left atrial hypertension [18].

This case report serves to highlight the caution that must be taken with the perioperative administration of a single unit of platelets due to the rare risk of transfusion-related injury manifesting as TRALI. After receiving only one unit of platelets, while undergoing a major surgical procedure, the 66-year-old patient succumbed to the complications related to TRALI. Currently, there are no other reports in the literature of TRALI development after the administration of only one unit of platelets. Overall, despite TRALI development being rare after sole administration of an all-plasma blood product, the significant morbidity and mortality associated with TRALI make consideration of predisposing factors of transfusion-related injury essential in the management of patients receiving such products in the perioperative setting.

Case Presentation

A 66-year-old female with a medical history significant for hypertension, hyperlipidemia, hepatitis C, liver cirrhosis, tobacco use disorder, metastatic spindle cell carcinoma of the lung status post carboplatin/pemetrexed/pembrolizumab chemotherapy, on pemetrexed/pembrolizumab for maintenance, recurrent pleural effusion, and recent positive positron emission tomography (PET) scan for enlarged mediastinal lymph nodes suspicious for malignancy. The patient presented to the operating room for fiberoptic bronchoscopy with ultrasound biopsy, right video-assisted thoracoscopy, robotic-assisted drainage of right pleural effusion, right lower lobe wedge resection, and talc pleurodesis. Pre-operative work-up was unremarkable except for a low platelet count of 55,000 (N: 150-450 $10^3/\mu\text{L}$) and a chest X-ray (CXR) indicative of trace small bilateral pleural effusions with associated bibasilar atelectasis. In the holding area, two large bore IVs and a radial arterial line were placed. Induction and intubation were uneventful while total IV anesthesia (propofol and remifentanyl) was used for maintenance of anesthesia. Endobronchial ultrasound was performed to identify the enlarged right hilar mediastinal lymph nodes. Transbronchial needle biopsy of these enlarged mediastinal lymph nodes and additional lymph nodes at this level were performed using a 19 Vizi-Shot needle (Olympus, PA, USA). A pathological review of these samples was deemed benign.

The decision was made to proceed with a right robot-assisted thoracoscopy instead of thoracentesis due to the large amounts of blood visualized during biopsy and the low preoperative platelet count. The ninth intercostal space at the right posterior axillary line was entered, and a moderate-sized effusion of serous fluid was visualized with the presence of fibrin in the pleural cavity causing loculations. This fluid was suctioned, and the remaining two robotic ports were placed at the nipple line and mid-axillary line of the right seventh intercostal space. At the level of the right lower lobe, near the inferior pulmonary ligament, the lung presented a multilobular appearance with induration that would be expected to be found with a lung nodule. An Endo-GIA 60 purple load (Medtronic, NH, USA) was placed, samples were taken for pathological review, and talc pleurodesis was performed. Intraoperatively, the surgeon observed significant microvascular bleeding. In response to the surgeon's observation and preoperative thrombocytopenia, a bag of platelets was transfused. In addition to the platelets, the patient received 700 mL of IV crystalloids throughout the case. At the conclusion of the surgery, neuromuscular blockade was reversed and the patient was found to be hemodynamically stable, achieving adequate tidal volumes, and following commands appropriately. The patient was extubated and was able to maintain an unobstructed upper airway without assistance. Within a few minutes, the patient became increasingly tachypneic with a respiratory rate of 35 breaths per minute and showed a rapid progression to hypoxia with a SaO₂ of 87%, requiring immediate reintubation while still in the operating room. Auscultation revealed rales in all lung fields. A CXR demonstrated interval development of diffuse, bilateral interstitial infiltrates suggestive of pulmonary edema (Figure 1). The patient was transferred to the postoperative anesthesia care unit (PACU) intubated on mechanical ventilation. A workup was done including labs (Table 1). Swan-Ganz catheter (Edwards Lifesciences, CA, USA) placement showed a pulmonary artery pressure of 26/15 mmHg with a central venous pressure of 8 mmHg. A repeat CXR showed worsening infiltrates bilaterally likely due to worsening pulmonary edema (Figure 2). A transthoracic echocardiogram revealed moderately impaired left ventricular (LV) systolic function with a left ventricular ejection fraction (LVEF) of 40%. The right ventricular size and systolic function were normal. Troponin levels were within normal limits. Given these findings, the patient's acute decompensation was determined to be consistent with TRALI. The patient was then transferred to the surgical intensive care unit (SICU) where she continued to deteriorate, eventually progressing to multiorgan failure with expiration on postoperative day six. Further testing by the blood center failed to identify anti-human leukocyte antigen (HLA) Class I & II, and anti-human neutrophil antigen (HNA) antibodies in the subsequent sample from the implicated donor. While this result rules out the immunogenic cause of TRALI, one may still consider a probable TRALI of non-immunogenic etiology. The case report presented is in accordance with Case Report Guidelines (CARE) (see the figure in the Appendix).




FIGURE 1: Chest X-ray displaying diffuse bilateral interstitial and airspace opacities suggestive of pulmonary edema.

Variable	Result	Reference values
WBC	19.2	4.8-10.8 10 ³ /uL
Platelets	132,000	150-450 10 ³ /uL
CO2	19.0	21.0-32.0 mmol/L
Chloride	110	98-107 mmol/L
Creatinine	1.21	0.55-1.02 mg/dL
Calcium	7.6	8.5-10.1 mg/dL

TABLE 1: Laboratory values in the PACU.

PACU, post anesthesia care unit; WBC, white blood count; CO2, carbon dioxide; uL, microliter; mmol, milimole per liter; mg, milligram; L, liter; dL, deciliter




FIGURE 2: Chest X-ray displaying worsening infiltrates bilaterally likely due to worsening pulmonary edema.

Discussion

The TRALI was first described in 1983 by Popovsky et al. when following five patients who developed signs of fever, acute hypoxemia, hypotension, respiratory distress, and non-cardiogenic pulmonary edema within four hours of blood product transfusion [19]. TRALI currently is the leading cause of transfusion-related mortality and warrants careful approach and frequent monitoring during blood transfusions, especially in those who are more vulnerable for acquiring TRALI [4]. Some of the risk factors for developing TRALI include patients with malignancies, shock, positive intravascular fluid balance, systemic inflammation, high peak airway pressure during mechanical ventilation, low interleukin-10 levels, and those undergoing liver and cardiovascular surgery [20]. It is estimated that nearly one in every 5000 blood transfusions is complicated by the development of TRALI [2].

Understanding of the pathophysiology behind TRALI remains incomplete, though it is contemporarily described as a process requiring two distinct events in succession. First, the transfusion recipient would have a certain baseline amount of inflammation present which sensitizes resident neutrophils in the lungs [21]. The presence of inflammation serves to increase the overall risk of transfusion-related injury followed by the second event which is the activation of neutrophils by antibodies, lipids, extracellular vesicles, or signaling molecules present in the transfused product [21]. This neutrophilic activation leads to even greater levels of localized inflammation, further damaging lung tissue and pulmonary blood vessel linings which ultimately leads to non-cardiogenic pulmonary edema and respiratory distress [21]. This is why every case of TRALI should be reported to the blood bank so that donors who might potentially cause the same reaction, in future recipients, are identified [22].

Transfusion-associated circulatory overload is the second leading cause of transfusion-related mortality and can easily be confused with TRALI given their similar course of symptomatology following transfusion [23]. Whereas both TACO and TRALI feature acute respiratory distress secondary to pulmonary edema, the absence of signs of circulatory overload distinguishes TRALI from the other [24]. In this case, the patient's symptoms were consistent with the expected presentation of TRALI given their normal central venous pressure, normal pulmonary artery wedge pressure, absence of S3 on auscultation, near normal LV function, and no signs of peripheral edema on physical exam (Table 2).


TRALI characteristics [17]	
Diagnostic feature	Quantitative or qualitative measure
Acute presentation of respiratory distress	Onset within 6 h of blood transfusion
Hypoxemia	SPO2 <90% or PaO2/FiO2 < 300 mmHg on room air
Pulmonary edema	Chest X-ray displaying bilateral infiltrates
Risk factors	Sepsis, pneumonia, acute pancreatitis, aspiration, multiple trauma
Increased end-diastolic volumes in critically ill patients	BNP >250 pg/mL or pre-/posttransfusion BNP ratio >1.5

TABLE 2: Diagnostic characteristics of TRALI.

TRALI, transfusion related acute lung injury; SPO2, oxygen saturation; PaO2, arterial partial pressure of oxygen; FiO2, fraction of inspired oxygen; pg, picogram; mL, milliliter; BNP, B-type natriuretic peptide

The differential diagnosis for patients presenting with TRALI-like symptoms should include other complications that originate from transfusion of blood products. Allergic and anaphylactic transfusion reactions also present with respiratory distress and hypoxia due to bronchospasm and laryngeal edema following transfusion of blood products [15-16]. The absence of wheezing, urticarial rash, and hypotension help rule out allergy and anaphylaxis as possible diagnoses [15-16]. Negative pressure pulmonary edema (NPPE) is an uncommon complication of anesthesia usually resulting from laryngospasm after extubation (approximately 0.1%). The most common risk factors include young age, male sex, and head or neck surgery. NPPE is an example of a noncardiogenic pulmonary edema that could resemble TRALI. The mechanism of NPPE is similar to hydrostatic pulmonary edema as observed in patients suffering from congestive heart failure or volume overload states [25-28]. The absence of upper airway obstruction rules out this etiology.

This case report highlights the importance of identifying predisposing risk factors prior to the utilization of blood products. This patient's risk factors included malignancy, liver disease, history of smoking, lung disease, and alcohol use disorder which predisposed her to developing TRALI. In this patient, TRALI manifested with dyspnea, tachypnea, and desaturation. TACO was ruled out by transthoracic echocardiography and Swan-Ganz monitoring showing no signs of fluid overload. Despite administering furosemide, the symptoms of the patient did not improve which is consistent with the usual course of TRALI in that nearly 70% of TRALI patients face worsening pulmonary symptoms, requiring them to be placed on mechanical ventilation. Further, the mechanism behind the hemodynamic instability in this patient is still not clear. The normal pulmonary artery pressure of 25/16 mmHg and central venous pressure (CVP) argue against fluid overload and myocardial ischemia (Figure 3).



Conclusions

Anesthesiologists are important in the recognition and initial treatment of TRALI, given their association with another contributor to TRALI development. Although TRALI has traditionally been understood to be a two-hit process, there is a possible third contributor to the process as well. Like the two-hit model, patient factors serve as the first hit which predisposes them to TRALI when receiving the transfusion which acts as the second hit. Additionally, the third hit is surgery, which is known to increase inflammatory markers, thereby increasing the chances of perioperative TRALI. Given their role in supervising many transfusions, anesthesiologists should screen for high-risk patients preoperatively. Overall, the best way to reduce TRALI cases is to minimize the number of unnecessary blood transfusions administered to patients. Considering that TRALI does not have a specific treatment option, it is essential that emphasis be placed on prevention. This case is unique in that administration of only one unit of platelets led to the development of TRALI. In conclusion, this case report highlights the importance of assessing the risk of TRALI when a blood transfusion is contemplated during surgery.

Appendices

CARE Checklist of information to include when writing a case report			
Topic	Item	Checklist item description	Reported on Line
Title	1	The diagnosis or intervention of primary focus followed by the words "case report"	✓
	2	2 to 5 key words that identify diagnoses or interventions in this case report, including "case report"	✓
Key Words	3a	Introduction: What is unique about this case and what does it add to the scientific literature?	✓
	3b	Main symptoms and/or important clinical findings	✓
	3c	The main diagnoses, therapeutic interventions, and outcomes	✓
	3d	Conclusion—What is the main "take-away" lesson(s) from this case?	✓
Introduction	4	One or two paragraphs summarizing why this case is unique (may include references)	✓
Patient Information	5a	De-identified patient specific information	✓
	5b	Primary concerns and symptoms of the patient	✓
	5c	Medical, family, and psycho-social history including relevant genetic information	✓
	5d	Relevant past interventions with outcomes	✓
Clinical Findings	6	Describe significant physical examination (PE) and important clinical findings	✓
	7	Historical and current information from this episode of care organized as a timeline	✓
Timeline	8a	Diagnostic testing (such as PE, laboratory testing, imaging, surveys)	✓
	8b	Diagnostic challenges (such as access to testing, financial, or cultural)	N/A
	8c	Diagnosis (including other diagnoses considered)	✓
	8d	Prognosis (such as staging in oncology) where applicable	N/A
Therapeutic Intervention	9a	Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care)	✓
	9b	Administration of therapeutic intervention (such as dosage, strength, duration)	✓
	9c	Changes in therapeutic intervention (with rationale)	✓
Follow-up and Outcomes	10a	Clinician and patient-assessed outcomes (if available)	✓
	10b	Important follow-up diagnostic and other test results	✓
	10c	Intervention adherence and tolerability (How was this assessed?)	✓
	10d	Adverse and unanticipated events	✓
Discussion	11a	A scientific discussion of the strengths AND limitations associated with this case report	✓
	11b	Discussion of the relevant medical literature with references	✓
	11c	The scientific rationale for any conclusions (including assessment of possible causes)	✓
	11d	The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion	✓
Patient Perspective	12	The patient should share their perspective in one to two paragraphs on the treatment(s) they received	N/A
	13	Did the patient give informed consent? Please provide if requested	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> N/A

FIGURE 4: CARE checklist.

The case report presented is in accordance with Case Report Guidelines (CARE).

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

- Popovsky MA, Moore SB: Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. *Transfusion*. 1985, 25:573-577. [10.1046/j.1537-2995.1985.25686071434.x](https://doi.org/10.1046/j.1537-2995.1985.25686071434.x)
- Roubinian N: TACO and TRALI: biology, risk factors, and prevention strategies. *Hematol Am Soc Hematol Educ Prog*. 2018, 2018:585-594. [10.1182/asheducation-2018.1.585](https://doi.org/10.1182/asheducation-2018.1.585)
- Silliman CC, Fung YL, Ball JB, Khan SY: Transfusion-related acute lung injury (TRALI): current concepts and misconceptions. *Blood Rev*. 2009, 23:245-255. [10.1016/j.blre.2009.07.005](https://doi.org/10.1016/j.blre.2009.07.005)
- Holness L, Knippen MA, Simmons L, Lachenbruch PA: Fatalities caused by TRALI. *Transfus Med Rev*. 2004, 18:184-188. [10.1016/j.tmr.2004.03.004](https://doi.org/10.1016/j.tmr.2004.03.004)
- Toy P, Gajic O, Bacchetti P, et al.: Transfusion-related acute lung injury: incidence and risk factors. *Blood*. 2012, 119:1757-1767. [10.1182/blood-2011-08-370932](https://doi.org/10.1182/blood-2011-08-370932)
- Looney MR, Roubinian N, Gajic O, et al.: Prospective study on the clinical course and outcomes in transfusion-related acute lung injury. *Crit Care Med*. 2014, 42:1676-1687. [10.1097/CCM.0000000000000323](https://doi.org/10.1097/CCM.0000000000000323)
- Toy P, Bacchetti P, Grimes B, et al.: Recipient clinical risk factors predominate in possible transfusion-related acute lung injury. *Transfusion*. 2015, 55:947-952. [10.1111/trf.12954](https://doi.org/10.1111/trf.12954)
- Triulzi DJ, Kleinman S, Kakaiya RM, et al.: The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. *Transfusion*. 2009, 49:1825-1835. [10.1111/j.1537-2995.2009.02206.x](https://doi.org/10.1111/j.1537-2995.2009.02206.x)
- Strait RT, Hicks W, Barasa N, et al.: MHC class I-specific antibody binding to nonhematopoietic cells drives complement activation to induce transfusion-related acute lung injury in mice. *J Exp Med*. 2011, 208:2525-2544. [10.1084/jem.20110159](https://doi.org/10.1084/jem.20110159)
- Otrock ZK, Liu C, Grossman BJ: Transfusion-related acute lung injury risk mitigation: an update. *Vox Sang*. 2017, 112:694-703. [10.1111/vox.12573](https://doi.org/10.1111/vox.12573)
- Sachs UJ, Hattar K, Weissmann N, Bohle RM, Weiss T, Sibelius U, Bux J: Antibody-induced neutrophil activation as a trigger for transfusion-related acute lung injury in an ex vivo rat lung model. *Blood*. 2006, 107:1217-1219. [10.1182/blood-2005-04-1744](https://doi.org/10.1182/blood-2005-04-1744)

12. Peters AL, van Hezel ME, Juffermans NP, Vlaar AP: Pathogenesis of non-antibody mediated transfusion-related acute lung injury from bench to bedside. *Blood Rev.* 2015, 29:51-61. [10.1016/j.blre.2014.09.007](#)
13. Juffermans NP, Vlaar AP: Possible TRALI is a real entity. *Transfusion.* 2017, 57:2539-2541. [10.1111/trf.14236](#)
14. Toy P, Kleinman SH, Looney MR: Proposed revised nomenclature for transfusion-related acute lung injury. *Transfusion.* 2017, 57:709-713. [10.1111/trf.13944](#)
15. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA: Proceedings of a consensus conference: towards an understanding of TRALI. *Transfus Med Rev.* 2005, 19:2-31. [10.1016/j.tmr.2004.10.001](#)
16. Hirayama F: Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment. *Br J Haematol.* 2013, 160:434-444. [10.1111/bjh.12150](#)
17. Gajic O, Gropper MA, Hubmayr RD: Pulmonary edema after transfusion: how to differentiate transfusion-associated circulatory overload from transfusion-related acute lung injury. *Crit Care Med.* 2006, 34:S109-S113. [10.1097/01.CCM.0000214311.56231.23](#)
18. Marik PE, Corwin HL: Acute lung injury following blood transfusion: expanding the definition. *Crit Care Med.* 2008, 36:3080-3084. [10.1097/CCM.0b013e31818c3801](#)
19. Popovsky MA, Abel MD, Moore SB: Transfusion-related acute lung injury associated with passive transfer of antileukocyte antibodies. *Am Rev Respir Dis.* 1983, 128:185-189. [10.1164/arrd.1983.128.1.185](#)
20. Semple JW, Rebetz J, Kapur R: Transfusion-associated circulatory overload and transfusion-related acute lung injury. *Blood.* 2019, 133:1840-1853. [10.1182/blood-2018-10-860809](#)
21. Silliman CC, Voelkel NF, Allard JD, Elzi DJ, Tuder RM, Johnson JL, Ambruso DR: Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. *J Clin Invest.* 1998, 101:1458-1467. [10.1172/JCI1841](#)
22. Wendel S, Biagini S, Trigo F, et al.: Measures to prevent TRALI. *Vox Sang.* 2007, 92:258-277. [10.1111/j.1423-0410.2006.00870.x](#)
23. Okazaki H: [Transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO)]. *Rinsho Byori.* 2013, 61:399-406.
24. Murphy EL, Kwaan N, Looney MR, et al.: Risk factors and outcomes in transfusion-associated circulatory overload. *Am J Med.* 2013, 126:357.e29-357.e38. [10.1016/j.amjmed.2012.08.019](#)
25. Lemyze M, Mallat J: Understanding negative pressure pulmonary edema. *Intens Care Med.* 2014, 40:1140-1143. [10.1007/s00134-014-3307-7](#)
26. Bux J: Transfusion-related acute lung injury (TRALI): a serious adverse event of blood transfusion. *Vox Sang.* 2005, 89:1-10. [10.1111/j.1423-0410.2005.00648.x](#)
27. McVey MJ, Kapur R, Cserti-Gazdewich C, Semple JW, Karkouti K, Kuebler WM: Transfusion-related acute lung injury in the perioperative patient. *Anesthesiology.* 2019, 131:693-715. [10.1097/ALN.0000000000002687](#)
28. Middelburg RA, van der Bom JG: Transfusion-related acute lung injury not a two-hit, but a multicausal model. *Transfusion.* 2015, 55:953-960. [10.1111/trf.12966](#)